EFFECTIVENESS AND SAFETY OF HIGH DOSE ORAL IBUPROFEN VERSUS STANDARD DOSE FOR TREATMENT OF PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS

  • Yaowaret Mekkhayai Chiangrai Prachanukroh Hospital
  • Chuleegone Sornsuvit Faculty of Pharmacy, Chiang Mai University, cDepartment of Pediatrics, Chiangrai Prachanukroh Hospital
  • Kanchana Preedisripipat Chiangrai Prachanukroh Hospital
  • Sorawit Pongpittayut Chiangrai Prachanukroh Hospital

Abstract

Objective: The objective of this research compares effectiveness and safety of high-dose oral ibuprofen and standard dose for treatment symptomatic PDA.

Methods: A retrospective cohort study was carried out in 126 preterm infants with patent ductus arteriosus (PDA) who received oral ibuprofen and hospitalized in neonatal intensive care unit and sick newborn ward during January 2010-December 2014, preterm infants with PDA was assigned to high dose (10-10-10 mg/kg/day) oral ibuprofen group and standard dose group (10-5-5 mg/kg/day), 63 patients within in each group.

Results: Baseline characteristics were no significant difference between two groups. The closure rate of the ductus arteriosus of the high dose group was significantly higher (82.5%) than in standard dose group (66.7%) (p=0.04). So, lower rate of re-open and PDA ligation. However, ductus arteriosus closure rate at discharge was not significantly different. There was no significant difference between two groups in adverse drug reaction.

Conclusion: The results obtained for this study show the high dose of oral ibuprofen is more effectiveness than the standard dose for closing PDA in preterm infants without increasing the adverse drug reaction rate.

 

Keywords: Preterm, Oral ibuprofen, Patent ductus arteriosus

Downloads

Download data is not yet available.

References

1. Saraiorn T. Acyanotic congenital heart disease. In: Somboon J, Arucha J, Chanathip L, Olarn P, Kedsara A, Pirot J. editors. Pediatrics 2. 1st ed. Bangkok: Nopachai printing; 2555. p. 992-1002.
2. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117:1113-21.
3. Vasita J, Kriengsak A, Prapaisree S. Incidence of patent ductus arteriosus (PDA) in preterm infants of gestational age less than 33 w at NICU bhumibol adulyadej hospital between 2005-2007. Royal Thai Airforce Medical Gazette 2009;55:17-27.
4. Supawat B. Problem and disorder in neonatal. In: Somboon J, Arucha J, Chanathip L, Olarn P, Kedsara A, Pirot J, editors. Pediatrics 2. 1st ed. Bangkok: Nopachai printing; 2555. p. 224-48.
5. Hamrick E, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010;125:1020-30.
6. Yang EM, Song ES, Choi YY. Comparison of oral ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in extremely low birth weight infants. J Pediatr 2013;89:33-9.
7. Gokman T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus artriosus. J Pediatr 2011;158:549-54.
8. Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen U. Oral versusintravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birth weight infants. Arch Dis Child-Fetal Neonatal Ed 2012;97:279-83.
9. Neumann R, Schulzke SM, Buhrer C. Oral ibuprofen versus intravenous ibuprofenor intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012;102:9-15.
10. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005;30:121-32.
11. Hirt D, Overmeire BV, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus. Br J Clin Pharmacol 2008;65:629-36.
12. Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clin Pharmacol Ther 2012;91:590-6.
13. Varaporn S, Chaisit S, Chanchai R, Korbtham S, Wiboon K, Meera K, et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai 2006;89:314-21.
14. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007;151:629-34.
15. Nizarali Z, Marques T, Costa C, Barroso R, Cunha M. Patent ductus arteriosus: perinatal risk factors. J Neonatal Biol 2012;1:1-4.
16. Reese J, Veldman A, Shah L, Vucovich M, Cotton RB. Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Seminars Perinatol 2010;34:222-30.
17. Thongchai K. Non steroidal anti-inflammatory drugs. J Med Sci 2010;17:98-106.
Statistics
346 Views | 464 Downloads
How to Cite
Mekkhayai, Y., C. Sornsuvit, K. Preedisripipat, and S. Pongpittayut. “EFFECTIVENESS AND SAFETY OF HIGH DOSE ORAL IBUPROFEN VERSUS STANDARD DOSE FOR TREATMENT OF PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 11, Aug. 2015, pp. 338-41, https://innovareacademics.in/journals/index.php/ijpps/article/view/8287.
Section
Original Article(s)